---
created: 2025-04-13
updated: 2025-04-13T10:53
id: PJJ:^t[hd9
specialty: pharmaco
specialty_id: 341
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::*basics
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::21-cetuximab-panitumumab
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::23-rituximab
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::23-rituximab::*basics
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::07-immunology
  - "source/ak-step1-v11:": 
  - theme/pixorize::02-biochem::22-onc-drugs::02-rituximab
  - "source/ak-step1-v11:": 
  - theme/pixorize::02-biochem::22-onc-drugs::03-cetuximab,-panitumumab
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::11-oncology::cetuximab,-panitumumab
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::11-oncology::rituximab
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::03-kinase-inhibitors-&-monoclonal-antibodies::02-rituximab,-cetuximab,-bevacizumab,-alemtuzumab,-trastuzumab::zanki-extra
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^highyield::3-highyield-temporary"
type: flashcard
---

# Question
Chimeric biologics can be recognized as their names will include the infix -**xi**-

---

# Answer
(ex Rituximab, Cetuximab)   Chimeric biologics are part animal-part human in its origin - therefore the immune system will think this biologic is a bad guy and generate antibodies against it